Standard Article

HIV Therapeutics, Biochemistry of


  1. Raveendra Dayam,
  2. Nouri Neamati

Published Online: 15 SEP 2006

DOI: 10.1002/3527600906.mcb.200400128

Reviews in Cell Biology and Molecular Medicine

Reviews in Cell Biology and Molecular Medicine

How to Cite

Dayam, R. and Neamati, N. 2006. HIV Therapeutics, Biochemistry of. Reviews in Cell Biology and Molecular Medicine. .

Author Information

  1. University of Southern California, Los Angeles, CA

Publication History

  1. Published Online: 15 SEP 2006


Although significant progress has been made in the treatment of HIV infection, we are still far from wining the battle. The combination of highly active antiretroviral therapy (HAART) in compliant patients comes close to stopping virus evolution; however, eradication of the infection has not been achieved because of the persistence of latent HIV-1 in resting memory CD4+ T cells. Moreover, several factors including the emergence of multidrug-resistant HIV strains, drug toxicity, the patient's ability to adhere to the prescribed therapy, and expensive medication have necessitated a reason to develop novel drugs and novel approaches to combat HIV infection.

Currently, the HAART regimen consists of nucleoside and nonnucleoside reverse transcriptase (RT) combined with protease (PR) inhibitors. This article summarizes all currently approved drugs for HIV-1 infection as well as drugs that have made significant progress in clinical trials but have not yet been approved. Where appropriate, their mechanism of action, mechanism of resistance, and toxicity are discussed


  • HAART;
  • Multidrug-resistant HIV Strain;
  • Allosteric Binding Site;
  • Peptidomimetic;
  • Nucleoside;
  • Nucleotide;
  • Transition State;
  • Lipodystrophy;
  • Cytochrome P-450